Chemotherapy Could Prime Tumors for PD-1 Blockade
Induction strategies in triple negative breast cancer enhanced sensitivity to PD-1 blockade.
Breast Cancer News
BREAST CANCER ADVISOR
Breast Cancer News
Bioimpedance Spectroscopy May Identify Lymphedema Earlier
Use of an electrical current to measure extracellular fluid volume — bioimpedance spectroscopy (BIS) — may identify postoperative breast cancer patients at risk for lymphedema at an earlier stage, when intervention may more effectively prevent progression.
Mammo-Based Deep Learning Model Assesses Breast Cancer Risk
Mammography-based deep learning (DL) breast cancer risk models are more accurate than models that consider traditional risk factors and breast density.
Test Predicts Benefit of Chemo in ER+, HER2− Breast Cancer
EndoPredict (EPclin) is prognostic for distant recurrence (DR) in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
New Lesions ID’d on Breast MRI During Treatment Likely Benign
magnetic resonance imaging (MRI) examinations with new suspicious findings are unlikely to represent a new site of malignancy
Clinicians Believe Link Between Breast Pain, Cancer Is Weak
Although most believe that the correlation between breast pain and breast cancer is weak, many referring clinicians will order imaging.
Kadcyla Approved as Adjuvant Treatment for HER2-Positive Early Breast Cancer
The FDA has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.The ‘KATHERINE’ trial evaluated the safety and efficacy of Kadcyla vs trastuzumab.
Risk-Based Breast Cancer Screening Guidelines from the American Society of Breast Cancer Surgeons
These guidelines remove ambiguity regarding screening mammography recommendations for women in their 40s.
FDA: Breast Implants Linked to Cancer Can Still Be Sold in US
Agency considering new patient warnings and checklists for the implants.
Radiotherapy Tied to Lower Recurrence of Early, Hormone-Driven Breast Cancer
Women with early, low-risk, hormone-driven breast cancer are less likely to have a recurrence of their disease if they have radiotherapy after surgery.
Long-Term HannaH Data Support Subcutaneous Trastuzumab for Breast Cancer
Subcutaneous trastuzumab was determined noninferior to intravenous trastuzumab for patients with HER2-positive early breast cancer.
Intraoperative Lidocaine May Reduce Breast Cancer Surgery-Associated Neuropathic Pain
Large studies examining the efficacy of intraoperative lidocaine infusions on breast cancer surgery-associated pain were found to be feasible.
Personalizing Breast Cancer Tx Could Cut Initial Costs of Care
Small decline seen in costs in first 12 months of care with personalized treatment based on recurrence scores
Genetic Testing Underused in Breast, Ovarian Cancer
Pathogenic variants ID’d in 7.8 percent of patients with breast cancer, 14.5 percent with ovarian cancer
Two RNA Sequencing Inflammatory Scores as Predictors of Benefit From Pembrolizumab in Advanced Breast Cancer
The search for robust biomarkers in the tumor immune microenvironment that could be predictive of response to immune checkpoint blockade is ongoing.
NCI-MATCH: No Objective Responses to Palbociclib in Patients With CCND-Amplified Tumors
In the palbociclib/CCND-amplification arm of the NCI MATCH trial, 42% of patients had received more than 4 prior lines of therapy.
High Baseline Inflammatory Biomarker Levels Linked to Shorter OS in mTNBC
On multivariate analyses, high baseline levels of IL-6 and CRP, but not IL-8, were associated with shorter OS in patients with breast cancer receiving atezolizumab.
Immune Biomarkers as Predictors of Response to Checkpoint Blockade in Breast Cancer
Results from this study showed that a close spatial distribution between CD3-positive T cells and cancer cells was a biomarker for response to pembrolizumab.
A Mechanistic Model of Drug Resistance in ER-Positive, PIK3CA-Mutant Breast Cancer
Resistance genes were found to be cell-line–specific.
OS Benefit to Adding Fulvestrant to First-Line Anastrozole in HR-Positive Metastatic Breast Cancer
The survival benefit of anastrozole/fulvestrant combination therapy was more pronounced in the subgroup of patients who did not have prior exposure to tamoxifen.
Want to read more?
Please login or register first to view this content.
